{
  "pmcid": "12140682",
  "sha256": "e9b7ca6561c7cc780fdd3793a752166fa7fd52ac227f3fa66c072eeeeccf535e",
  "timestamp_utc": "2025-11-09T23:28:04.594068+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.107668217054265,
    "reading_ease": 48.146246511627936,
    "word_count": 258
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial Comparing Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This meta-analysis included eight randomised controlled trials (RCTs) with a total of 18,671 patients."
      },
      "Participants": {
        "score": 1,
        "evidence": "Studies comparing TAVR and SAVR outcomes in adults were included."
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study aims to compare the outcomes of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with aortic stenosis (AS)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to compare the outcomes of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with aortic stenosis (AS)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was all-cause mortality at 30 days."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 18,671 patients were randomised, with 9,336 to TAVR and 9,335 to SAVR."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "All-cause mortality was lower in the TAVR group (2.48% vs. 3.03%), with an odds ratio (OR) of 0.79 (95% CI: 0.63â€“1.00; P = 0.05)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not detailed."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The study was registered in the Open Science Framework (OSF.IO/X35KY)."
      },
      "Funding": {
        "score": 0,
        "evidence": "The study was funded by unspecified sources."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}